INEX Announces that GlaxoSmithKline has Filed an

 Investigational New  


    Drug Application for Topotecan Formulated with INEX's Drug Delivery 
    Technology


VANCOUVER, April 16 /CNW/ - Inex Pharmaceuticals Corporation ("INEX";
TSX: IEX) announced today that GlaxoSmithKline ("GSK"; LSE and NYSE: GSK) has
filed an Investigational New Drug application (IND) with the United States
Food and Drug Administration (FDA) asking for approval to begin human clinical
trials evaluating GSK's anticancer drug topotecan encapsulated in INEX's
proprietary drug delivery technology, known as Transmembrane Carrier System
(TCS). 
David Main, President and CEO of INEX, said INEX earned US$1.5 million in
the first quarter of 2003 in milestone payments to support the filing of the
IND and the ongoing development of the product. Since the two companies
entered their partnership in late 2001, GSK has paid INEX a total of US$4.5
million in upfront and milestone payments. 
INEX will qualify for additional milestone payments as GSK's drug moves
through clinical development and commercialization. GSK is responsible for all
development costs and INEX will receive a royalty on the drug's sales upon
commercialization. 
Encapsulating anticancer drugs inside INEX's proprietary TCS drug
delivery technology may provide prolonged blood circulation, accumulation in
tumors and extended drug release of the encapsulated drug at the cancer site. 
Topotecan is the second chemotherapeutic agent to be encapsulated using
INEX's TCS technology. The company's lead product, Onco TCS, is the
encapsulation of the anticancer drug vincristine. INEX plans to file in the
third of quarter of 2003 a New Drug Application for Onco TCS as a treatment
for relapsed aggressive non-Hodgkin's lymphoma. Onco TCS is also being
evaluated in several phase II clinical trials in combination and stand-alone
therapy for several other cancers. 
INEX is a Canadian biopharmaceutical company developing and
commercializing proprietary drugs and drug delivery systems to improve the
treatment of cancer. 
Statements contained herein that are not based on historical fact,
including without limitation statements containing the words "believes",
"may," "plans," "will," "estimate," "continue," "anticipates," "intends,"
"expects," and similar expressions, constitute "forward-looking statements".
Such forward-looking statements involve known and unknown risks, uncertainties
and other factors that may cause the actual results, events or developments to
be materially different from any future results, events or developments
expressed or implied by such forward-looking statements. Given these risks and
uncertainties, readers are cautioned not to place undue reliance on such
forward-looking statements. The Company disclaims any obligation to update any
such factors or to publicly announce the result of any revisions to any of the
forward-looking statements contained herein to reflect future results, events
or developments. 
INEX's common shares are traded on the Toronto Stock Exchange under the
trading symbol "IEX". 
-0-                           04/16/2003 
/For further information: INEX investor contact: Ian Mortimer, Director, 
Investor Relations, Inex Pharmaceuticals Corp., Tel: 604-419-3200, Email: 
info(at)inexpharm.com, Website: www.inexpharm.com; INEX media contact: Maria 
Loscerbo, James Hoggan & Associates Inc., Tel: 604-739-7500, Email: 
mloscerbo(at)hoggan.com/ 
(IEX.) 
CO:  Inex Pharmaceuticals Corporation
ST:  British Columbia
IN:  MTC 
SU:   
-30- 
-0- Apr/16/2003 12:30 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.